WESTMINSTER, Colo. (AP) —Allos Therapeutics Inc. said Monday a regulatory panel will review its cancer drug candidate pralatrexate on Sept. 2, sending Allos shares higher in morning trading. The company said a Food and Drug Administration cancer advisory committee will hold a meeting to review the drug. Pralatrexate is intended as a treatment for T-cell lymphoma that has recurred or not responded to other drugs. T-cell lymphoma is a type of cancer that attacks the immune system. A positive review improves the odds the FDA will approve pralatrexate; the agency is not required to follow the advice of its panels, but it often does so. The FDA is expected to make a ruling on pralatrexate by Sept. 24.